Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
Information source: Henry Ford Health System
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: ESRD
Intervention: Gentamycin/citrate, Minocycline/EDTA (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Henry Ford Health System Official(s) and/or principal investigator(s): Antanole Bearabe, MD, Principal Investigator, Affiliation: Henry Ford Hospital
Summary
To study the efficacy of an antibacterial/anticoagulant solution instilled into the
hemodialysis (HD) catheters after each treatment (“antibiotic lock solution - ALS”) to
prevent catheter related bacteremia (CRB) and to salvage catheters with established CRB.
Clinical Details
Study design: Prevention, Randomized, Open Label, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Primary outcome: Incidence of symptomatic CRB
Detailed description:
Scope of the problem. A large number of hemodialysis patients in this country rely on
indwelling tunneled and non-tunneled catheters as vascular access for hemodialysis even
though the K/DOQI guidelines discourage their use. In a study performed by ESRD network 11,
[to which all Michigan dialysis centers submit data] 63% of patients initiated HD with a
catheter as their sole form of vascular access. At 6 months after initiation of HD, 40% of
these patients were still using a catheter. Other studies had shown that the prevalence of
overall catheter use to be around 20% of all accesses.
Catheter associated infection. Current literature indicates that these catheters are
associated with a disproportionate risk for infection, particularly CRB, resulting in high
morbidity, mortality and healthcare expenditure. The ‘epidemic’ of ESRD in this country has
seen an ever increasing reliance on these catheters not only to initiate the HD but also for
long term treatment in those patients who have no other access options. It has been estimated
that intravascular catheters are associated with more than 60,000 cases of nosocomial
bacteremia each year. HD catheters pose a particularly high risk for developing infections
because of their frequent use as well as their long-term use. All indwelling vascular
catheters are colonized by micro-organisms within 24 hours after insertion. The deposition
of biofilm on the external and internal surface of vascular catheters is thought to play an
important role in the colonization process. The biofilm is produced by a combination of host
factors (e. g., fibrinogen, fibrin, fibronectin and extracellular polysaccharides) and
microbial products (e. g., glycocalyx or "slime").
Failure of antibiotics. Systemic antibiotics used to treat bacteremia do not penetrate
catheter lumen and therefore do not eradicate the biofilm, leading to potential treatment
failures and eventual sacrifice of the catheter. Recently published data suggests that using
a combination solution with antibacterial/anticoagulant agents prevents the formation of the
‘biofilm’ in the catheter lumen thereby preventing CRB, as well as salvage the catheters in
cases of established CRB. However, there continues to be a debate on the appropriate
antibacterial agent as well as its optimal concentration, in order to eradicate a wide
variety of organisms. Several other strategies were studied in the past 10 years to prevent
CRB and CRI. These include eradication of nasal Staphylococcal carriage with mupirocin,
using chlorhexidine for catheter hub cleaning and exit site disinfection and using mupirocin
or Polysporin ointments to the exit site along with standard dressing. But emergence of
antibiotic resistance as well as the high costs of administrating these methods continue to
be barriers to their widespread use and cannot be relied upon to manage the high rate of
infection by themselves.
Salvaging catheters. In the past, infected catheters were routinely removed, especially for
Staphylococcus aureus infections, per the CDC guidelines. However, recent small studies
indicate that strategies such as ALS packing or changing catheter over a guide wire can
salvage a significant fraction of these catheters, thereby saving expense and morbidity, and
preserving the site. Thrombotic occlusions and infection are the two most common
complications of the HD catheters, each predisposing to the other. Some studies have shown
that ALS packing has also improved the long-term catheter function by preventing the
formation and propagation of the biofilm. Studying this aspect of catheter maintenance is
also an important outcome for our proposed study.
Antibiotic Lock Solutions. We have identified 10 clinical trials (attached as appendix) in
the published literature describing the results of antibiotic lock therapy for preventing
infections in indwelling vascular catheters. All but one have demonstrated efficacy of ALS
packing. Of the 9 successful trials, only 6 were randomized controlled trials and only 3 of
these were done on HD catheters, as described below.
Need for a prospective study. If we can achieve the same superior results from our study
incorporating the ALS packing strategy, we should be able to assess cost- effectiveness of
using the ALS packing vs. standard approach as has been discussed in previous trials, but has
not been systematically studied. In fact there are insufficient numbers of patients studies
to even perform a meta-analysis. We feel that it is critical to prove the cost-effectiveness
of the new strategy in order for it to be used in a widespread fashion.
The applicant, Anatole Besarab MD, has extensive experience in Nephrology and specifically in
vascular access management. He has published, lectured, and coordinated symposia on vascular
access care and is the current chair of the K/DOQI vascular access workgroup of the NKF.
This project is conceived for the following reasons.
- The CRB burden in the hemodialysis patients at this institution has reached overwhelming
proportions and needs urgent strategies to counter this ‘epidemic’. Current management
guidelines rely mostly on treatment of established infections but do not aim at
preventing these infections. This kind of economic burden and increased
morbidity/mortality in patients are unacceptable in the current health care environment.
Our study will add to the existing literature in defining the management guidelines for
CRB.
- The Greenfield Health System (GHS) that provides dialysis care to the patients of the
Henry Ford Health System includes several hundreds of patients and would be the ideal
setting to study the proposed intervention. This population also represents a
cross-section of many types of disease severity and number of co-morbid conditions.
Therefore they provide an opportunity to observe the effects on the proposed
intervention in different demographic settings.
- Henry Ford Hospital represents a completely new demography to study the effects of the
proposed intervention. The disease burden with CRB in the population served by this area
is higher than the national average and would be ideal to study the proposed
intervention in more detail.
- The cost effectiveness of using the antibiotic lock therapy has not been well studied to
date and will have a significant impact on the eventual formulation of treatment
guidelines. In the setting of current economic burden in the health care industry, study
of this issue is vital and timely. The vision of a simple, cheap intervention that can
result in savings of millions of dollars is central to this study.
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- ESRD patients with tunnelled catheters
Exclusion Criteria:
- patients on IV abx for infections, patients who have AV graft, AV fistulas
Locations and Contacts
Henry Ford Hospital, Detroit, Michigan 48202, United States
Additional Information
Starting date: September 2003
Ending date: May 2004
Last updated: February 21, 2006
|